|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The database is the first comprehensive integration of disparate cancer genome data like single nucleotide variants, single nucleotide polymorphisms, and chromosomal aberrations (CGH and FISH).
|
20127971 |
2010 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination of microdissection and CGH enabled us to detect cytogenetic aberrations from important clones which are missed when analyzing DNA extracted from large cell numbers.
|
10214356 |
1999 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
|
16455056 |
2006 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.
|
24987674 |
2014 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, a Gaussian pdf is not adequate to approximate the noise in array CGH data and hence introduces wrong detections of chromosomal aberrations and leads misunderstanding on disease pathogenesis.
|
28692986 |
2019 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
More chromosome abnormalities are detected by conventional karyotyping compared to FISH or MLPA only (chromosome region specific techniques), and the same amount of abnormalities compared to QF-PCR (chromosome region specific techniques) and chromosomal-CGH and array-CGH (whole genome techniques) only.
|
22796359 |
2012 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The cytogenetic abnormality was investigated with FISH and array-CGH to characterize the breakpoints of the complex rearrangement.
|
22965227 |
2013 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The successful application of the CGH technique to the detection of aneuploidy in spontaneous abortions, demonstrates the utility of using this technique to screen prenatally for numerical chromosome abnormalities.
|
10215063 |
1999 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Monozygotic twins discordant for submicroscopic chromosomal anomalies in 2p25.3 region detected by array CGH.
|
23061379 |
2013 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These results lead to two conclusions: i) in the in vitro non-proliferating population of AML tumor cells one can detect cryptic chromosomal aberrations, which might constitute tumor markers of diagnostic and prognostic value; ii) The results of CGH need to be checked by other approaches.
|
16010415 |
2005 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with atypical values of HCG and/or PAPP-A are at higher risk of chromosomal abnormality and vascular complications of pregnancy.
|
31779618 |
2019 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Array CGH is becoming an important clinical assay for unbalanced chromosome abnormalities whether cells grow in culture or not and in cases of analysis on one or few cells.
|
16088865 |
2005 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
To explore the advantages and limitations of comparative genomic hybridization to BAC arrays (array CGH) for prenatal diagnosis of a fetus with anomalies and a chromosome abnormality.
|
18818501 |
2008 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Array CGH has recently been used to perform a genome-wide screen for submicroscopic gains and losses in individuals with a normal karyotype but with features suggestive of a chromosome abnormality.
|
16283669 |
2005 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In order to investigate the patterns of chromosomal aberrations in gastric carcinomas, we performed genome-wide microarray based comparative genomic hybridisation (microarray CGH).
|
15623941 |
2004 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The Cancer Chromosomes database integrates the SKY/M-FISH & CGH Database with the Mitelman Database of Chromosome Aberrations in Cancer and the Recurrent Chromosome Aberrations in Cancer database.
|
15934046 |
2005 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Fast approach for clarification of chromosomal aberrations by using LM-PCR and FT-CGH in leukaemic sample.
|
21986343 |
2012 |
|
Congenital chromosomal disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Eighteen children with acute myeloid leukemia (AML) (n=15) or myelodysplastic syndrome (MDS) (n=3) were studied using CGH+SNP microarray to evaluate the clinical significance of submicroscopic chromosomal aberrations.
|
25045224 |
2014 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Chromosomal aberrations in bladder cancer: fresh versus formalin fixed paraffin embedded tissue and targeted FISH versus wide microarray-based CGH analysis.
|
21909424 |
2011 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike metaphase CGH, the high resolution of array CGH in subtelomeric regions allows an accurate description of chromosomal aberrations.
|
21145667 |
2011 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
These results demonstrate that array-CGH is a powerful tool to screen MS tissue for unbalanced genomic abnormalities, allowing identification of chromosome abnormalities when concurrent BM is nonanalyzable or nonleukemic.
|
16080198 |
2005 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Our array CGH analysis detected an average of 83 chromosomal aberrations in 13 cases, ranging from 0 to 387.
|
24952511 |
2014 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
The main databases devoted stricto sensu to cancer cytogenetics are the "Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer" ( http://cgap.nci.nih.gov/Chromosomes/Mitelman ), the "Atlas of Genetics and Cytogenetics in Oncology and Haematology" ( http://atlasgeneticsoncology.org ), and COSMIC ( http://cancer.sanger.ac.uk/cosmic ).However, being a complex multistep process, cancer cytogenetics are broadened to "cytogenomics," with complementary resources on: general databases (nucleic acid and protein sequences databases; cartography browsers: GenBank, RefSeq, UCSC, Ensembl, UniProtKB, and Entrez Gene), cancer genomic portals associated with recent international integrated programs, such as TCGA or ICGC, other fusion genes databases, array CGH databases, copy number variation databases, and mutation databases.
|
27910033 |
2017 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Promising approaches and molecular markers include gene expression profiles, DNA ploidy, loss of heterozygosity and chromosomal aberrations as detected by CGH and FISH (1q, 17p, 17q), as well as oncogenes/ tumor suppressor genes and their proteins (TP53, PTEN, c-erbB2, N-myc, c-myc), growth factor and hormonal receptors (PDGFRA, VEGF, EGFR, HER2, HER4, ErbB-2, hTERT, TrkC), cell cycle genes (p27) and cell adhesion molecules, as well as factors potentially related to therapeutic resistance (multi-drug resistance, DNA topoisomerase IIalpha, metallothionein, P-glycoprotein, tenascin).
|
15624758 |
2004 |
|
Congenital chromosomal disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Screening large patient cohorts with mental retardation by array CGH has recently lead to the characterization of many novel microdeletion and microduplication syndromes, initially according to the shared cytogenetic aberrations, with secondary characterization of the corresponding phenotypes.
|
18512078 |
2008 |